Seeking Alpha
 

Rosetta Genomics Ltd. (ROSG)

- NASDAQ
  • Mon, Mar. 16, 4:43 PM
    • Rosetta Genomics (NASDAQ:ROSG): 2H14 EPS of -$1.21 vs. -$1.25 in 2H13
    • Revenue of $1.3M (+228.0% Y/Y).
    • Press Release
    | 4 Comments
  • Sep. 17, 2014, 5:36 PM
    • Rosetta Genomics (NASDAQ:ROSG): 1H14 EPS of -$0.62 vs. -$0.64 in 1H13.
    • Revenue of $0.55M (+187% Y/Y)
    • Shares +11.68% AH.
    • Press Release
    | Comment!
  • Sep. 17, 2014, 4:56 PM
    • Rosetta Genomics (ROSG +9.5%) 1H results: Revenues: $0.6M (+187.0%); Operating Expenses: $7.0M (+9.3%); Net Loss: ($7.2M) (-14.2%); Loss Per Share: ($0.66) (+7.0%); Quick Assets: $19.7M (-19.3%).
    • Cash guidance: cash required to fund operations through 2014: $14M - 15M (includes $7.5M consumed in 1H). The company believes its existing cash and projected revenues will be sufficient to fund operations into 2016.
    | Comment!
  • Sep. 10, 2013, 9:18 AM
    • Rosetta Genomics (ROSG): 1H13 EPS of -$0.64 vs. $3.25 in 1H12.
    • Revenue of $193K vs. 51K in 1H12. Shares +1.5% premarket. (PR)
    | Comment!
Visit Seeking Alpha's
ROSG vs. ETF Alternatives
Company Description
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.